You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 10,981,952


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,981,952 protect, and when does it expire?

Patent 10,981,952 protects BYLVAY and is included in one NDA.

This patent has sixty-three patent family members in thirty-one countries.

Summary for Patent: 10,981,952
Title:IBAT inhibitors for the treatment of liver diseases
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Inventor(s): Gillberg; Per-Goran (Molndal, SE), Graffner; Hans (Helsingborg, SE), Starke; Ingemar (Gothenburg, SE)
Assignee: Albireo AB (Goteborg, SE)
Application Number:16/737,742
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,981,952: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, researchers, and business professionals to navigate the complex landscape of intellectual property. This article will delve into the details of United States Patent 10,981,952, focusing on its claims, scope, and the broader patent landscape.

Overview of the Patent

United States Patent 10,981,952, titled "IBAT inhibitors for the treatment of liver diseases," pertains to specific inhibitors of the ileal sodium/bile acid cotransporter (IBAT) and their application in the prophylaxis and treatment of liver diseases. Here is a brief overview of the patent:

  • Publication Number: US10981952B2
  • Authority: United States
  • Prior Art Keywords: Include terms like "alkyl," "formula," "hydrogen," "phenyl," and others related to the chemical and biological aspects of the invention[4].

Claims Analysis

The claims section of a patent is critical as it defines the scope of protection granted to the inventor. Here’s a detailed look at the claims of US10981952B2:

Independent Claims

Independent claims are those that stand alone and do not depend on other claims. For US10981952B2, these claims typically describe the core invention, such as the specific IBAT inhibitors and their compositions.

  • Claim 1: This claim might describe the general composition of the IBAT inhibitors, including the chemical structure and any specific compounds or salts involved[4].

Dependent Claims

Dependent claims build upon the independent claims and provide additional details or specific embodiments of the invention.

  • Dependent Claims: These claims may include specific methods of treatment, dosages, formulations, and other detailed aspects of the IBAT inhibitors. For example, claims might describe the use of these inhibitors in treating non-alcoholic fatty liver disease, primary biliary cholangitis, or other liver-related conditions[4].

Scope of the Patent

The scope of a patent is determined by its claims and is a key factor in assessing the patent's validity and enforceability.

Metrics for Measuring Patent Scope

Research has identified simple metrics to measure patent scope, such as independent claim length and independent claim count. These metrics can indicate the breadth and clarity of the patent claims. For instance:

  • Independent Claim Length: Longer independent claims often indicate a narrower scope, as they provide more detailed descriptions of the invention[5].
  • Independent Claim Count: A higher number of independent claims can suggest a broader scope, but this can also lead to increased complexity and potential issues with clarity and validity[5].

Application to US10981952B2

For US10981952B2, the scope can be analyzed by examining the claim language and structure. If the independent claims are detailed and specific, it may indicate a narrower scope, which could be beneficial for clarity and enforceability. However, if the claims are broad and vague, it could lead to issues with patent quality and potential litigation.

Patent Landscape

Understanding the broader patent landscape is essential for contextualizing the significance and potential impact of US10981952B2.

Related Patents and Prior Art

The patent landscape includes other patents and prior art related to IBAT inhibitors and liver disease treatments. Tools like the USPTO's Patent Public Search, Global Dossier, and international patent databases can help identify these related patents and assess the novelty and non-obviousness of US10981952B2[1].

International Patent Offices

Searching international patent offices, such as the European Patent Office (EPO), Japan Patent Office (JPO), and World Intellectual Property Organization (WIPO), can provide insights into global patent filings related to IBAT inhibitors. This helps in understanding the global intellectual property landscape and potential competition or collaboration opportunities[1].

Economic and Legal Implications

The economic and legal implications of a patent are significant and can impact innovation, licensing, and litigation.

Patent Quality and Innovation

The quality of a patent, measured by its scope and claim clarity, can influence innovation. Narrower, clearer claims can reduce licensing and litigation costs, thereby encouraging innovation. Conversely, overly broad or vague claims can hinder innovation by creating uncertainty and increasing legal costs[5].

Licensing and Litigation

The scope and claims of US10981952B2 will play a crucial role in licensing agreements and potential litigation. Clear and specific claims can facilitate smoother licensing negotiations and reduce the risk of patent disputes.

Practical Applications

Understanding the scope and claims of US10981952B2 has practical implications for various stakeholders.

Researchers and Inventors

Researchers and inventors can use this analysis to understand the current state of the art in IBAT inhibitors and liver disease treatments. This knowledge can guide future research and development, ensuring that new inventions are novel and non-obvious over existing patents.

Business Professionals

Business professionals can use this analysis to assess the commercial potential of US10981952B2. By understanding the scope and claims, they can evaluate licensing opportunities, potential market competition, and the overall viability of the patent in the market.

Key Takeaways

  • Claims Analysis: The claims of US10981952B2 define the scope of protection and are crucial for understanding the patent's validity and enforceability.
  • Patent Scope: Metrics such as independent claim length and count can help measure the patent scope, indicating its breadth and clarity.
  • Patent Landscape: Understanding related patents and prior art is essential for assessing the novelty and non-obviousness of the invention.
  • Economic and Legal Implications: The quality of the patent can impact innovation, licensing, and litigation costs.
  • Practical Applications: The analysis is vital for researchers, inventors, and business professionals to navigate the intellectual property landscape effectively.

FAQs

What is the main subject of United States Patent 10,981,952?

The main subject of US10981952B2 is specific IBAT inhibitors and their application in the treatment of liver diseases.

How can the scope of a patent be measured?

The scope of a patent can be measured using metrics such as independent claim length and independent claim count.

What are the economic implications of patent scope?

The economic implications include the potential to reduce licensing and litigation costs, thereby encouraging innovation, if the patent claims are clear and specific.

Where can I find related patents and prior art for US10981952B2?

Related patents and prior art can be found using tools like the USPTO's Patent Public Search, Global Dossier, and international patent databases.

How does the quality of a patent impact innovation?

The quality of a patent, measured by its scope and claim clarity, can influence innovation by reducing uncertainty and legal costs, thus encouraging further research and development.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Unified Patents Portal - US-5578316-A: https://portal.unifiedpatents.com/patents/patent/US-5578316-A
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Google Patents - US10981952B2: https://patents.google.com/patent/US10981952B2/en
  5. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,981,952

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,981,952 ⤷  Subscribe METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Subscribe
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,981,952 ⤷  Subscribe METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Subscribe
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,981,952 ⤷  Subscribe METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Subscribe
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,981,952 ⤷  Subscribe METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Subscribe
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes 10,981,952 ⤷  Subscribe METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,981,952

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden1051165-7Nov 8, 2010

International Family Members for US Patent 10,981,952

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3400944 ⤷  Subscribe PA2021012 Lithuania ⤷  Subscribe
European Patent Office 3400944 ⤷  Subscribe LUC00242 Luxembourg ⤷  Subscribe
European Patent Office 3400944 ⤷  Subscribe 301157 Netherlands ⤷  Subscribe
European Patent Office 3400944 ⤷  Subscribe CA 2022 00001 Denmark ⤷  Subscribe
European Patent Office 3400944 ⤷  Subscribe 2021C/554 Belgium ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.